Rarecells CEO Prof. Patrizia Paterlini Discusses Detecting Cancer Before It Appears on Imaging on Newsmax’s Saturday Agenda New York, NY — September 26, 2026 Prof. Patrizia Paterlini, MD, PhD, founder and CEO of Rarecells, appeared on Newsmax’s Saturday Agenda on Saturday, September 26, 2026, to discuss how detecting tumor cells in the blood could allow […]
Patrizia Paterlini Interviewed by Newsmax Saturday Agenda Read More »
New York, NY, USA and Paris, France — May 12, 2026 — Rarecells, a pioneer in liquid biopsy technologies for early cancer detection, today announced that its proprietary ISET® diagnostic system has been recognized by the Innovation Value Institute at Maynooth University among the Top 5 Disruptive Health Technologies with the Potential to Change the
Hunting the “Invisible Enemy”: Liquid Biopsy and the Stage Zero Revolution Detecting cancer years before it becomes visible through traditional diagnostic tests. This is the wager of Prof. Patrizia Paterlini-Bréchot and the technology that isolates “sentinels” in the bloodstream. By Sergio Gentili (Translated from Italian: https://www.oncolife.it/news/biopsia-liquida/) December 22, 2025 For decades, oncology has operated according
NEW YORK and PARIS, September 9th, 2025 (GLOBE NEWSWIRE) – Rarecells, a pioneer in liquid biopsy technologies, today presented new data (poster EP.06.64) at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain, from its BioMolCTC Trial conducted in collaboration with Prof. Filippo Lococo’s team at Policlinico Gemelli in Rome. Circulating Tumor
Oncologist Patrizia Paterlini: «I look for tumor cells before the tumor becomes visible, which is why I patented a test that looks for tumor cells in the blood in the very early stages of development» “I chose research because, as an oncologist, I saw too many patients die—I felt powerless,” says the researcher who
Vanity Fair Italy Interviews Rarecells Founder Dr. Patrizia Paterlini Read More »
NEW YORK, NY and PARIS, FRANCE – June 18, 2025 Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership experience across private industry and academia. She has a distinguished track record of building
Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board Read More »
NEW YORK – (March 26, 2025) – Rarecells, Inc., a pioneering company in liquid biopsy, is pleased to announce the appointment of Dr. Neil Kurtz to its Board of Directors. Dr. Kurtz, a renowned healthcare entrepreneur and executive, brings over 40 years of experience in the pharmaceutical, contract research, post-acute care, and medical diagnostic sectors.
Press Release: Rarecells, Inc. Appoints Dr. Neil Kurtz to Board of Directors Read More »
NEW YORK, Sept. 6, 2022 /PRNewswire/ — Rarecells, Inc. today announced the appointment of Dr. Neil Gunn, a recognized leader and expert in the diagnostic space, as an independent Board Director. “We are delighted to welcome Neil as Board Director. With his broad understanding of diagnostics and the Liquid Biopsy space he is well-positioned to provide valuable perspectives
Press Release: Rarecells announces Appointment of New Director to the Board Read More »
Please enter the requested information below and click SEND
Please enter the requested information below and click SEND
Please enter the requested information below and click SEND